Becton Dickinson (BSP:B1DX34) Dividend-Payout-to-FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:B1DX34 Becton Dickinson & Co BSP:B1DX34
72 GF Score
Price R$183.73
GF Value R$160.60
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Becton Dickinson Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

BSP:B1DX34
72GF Score
Becton Dickinson & Co BSP:B1DX34
Dividend-Payout-to-FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Becton Dickinson (BSP:B1DX34) Overvalued in 2026?

Based on GuruFocus' analysis, Becton Dickinson stock appears to be overvalued. The current stock price of R$183.73 is trading 14.4% above its estimated GF Value™ of R$160.60. GuruFocus considers Becton Dickinson to be Modestly Overvalued.

Key valuation signals for BSP:B1DX34:

  • Dividend-Payout-to-FFO:
  • GF Value™: R$160.60 vs. price of R$183.73 (14.4% above fair value)
  • GF Score™: 72/100 with 7 warning signs

No single metric tells the full story. See the BSP:B1DX34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Becton Dickinson Business Description

Address 1 Becton Drive, Franklin Lakes, NJ, USA, 07417-1880
Becton, Dickinson and Company (BD) is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. It operates through segments including BD Medical, which supplies medication delivery and diabetes care products such as syringes, needles, catheters, and infusion pumps; BD Life Sciences, offering diagnostic systems, specimen collection products, and research reagents; and BD Interventional, providing surgical, vascular, and urology devices including hernia repair and biopsy products. Customers include hospitals, clinics, laboratories, physicians, and pharmaceutical companies, with products sold in more than 190 countries. Revenue comes primarily from device and consumable sales, supplemented by instrument placements and service contracts. The United States is its largest market, though it maintains significant operations across Europe, Asia, and emerging markets.
72GF Score

Get the complete analysis for BSP:B1DX34

Dividend-Payout-to-FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$183.73
Price
R$160.60
GF Value